Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Oocyte donation is a well established procedure in assisted reproduction treatments (ART). It
is demonstrated that the use of hormonal substitution therapy, for the synchronization of the
cycles between the recipients and the donors, provides good results, similar to the ones
obtained with the natural cycle. In the patients - recipients with preserved ovarian
function, the recipient's natural cycle is annulled, thus preventing the spontaneous
Luteinizing Hormone surge. Simultaneously and while waiting for the suitable donor, her
endometrium is prepared. When the donation occurs and fertilization with the husband sperm
takes place, her cycle is stimulated again in order to synchronize her window of implantation
with the donor's ovulation.
Two different medications are commonly used to inhibit spontaneous ovulation: either GnRHa
agonist or GnRH antagonists. The present study consists of the comparison between the single
dose GnRH agonist (Decapeptyl 3,75 IM) and the 7 day dosage of GnRH antagonist (Cetrotide
0,25 mg). The administration of GnRHa is used fundamentally as a long liberation formulation,
administered in a single intramuscular injection (IM), which is more practical in terms of
use. Nevertheless, the unnecessary persistence and the potentially unfavorable action of
GnRHa during the luteal phase and early gestation have questioned its use. The recovery of
the Hypophysarian function begins only 8 weeks after the single injection of long liberation
of triptorelina 3.75 mg. The GnRH antagonist (Cetrotide 0,25 mg) makes the hypofisary
inhibition shorter than with the analogues and can prepare similar endometrium
characteristics as a natural cycle. The recipients will be assigned randomly to a group of
treatment or another.
Phase:
Phase 4
Details
Lead Sponsor:
Instituto Valenciano de Infertilidad, IVI VALENCIA